Risultati per: Terapia sistemica del carcinoma epatocellulare

Objective
Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC).

Design
We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1, TP53, PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples.

Results
In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p

We read with great interest the recent article by Choi et al.1 By analysing the data of a multicentre historical cohort including 4693 adult patients with chronic hepatitis B (CHB), they concluded that patients with moderate baseline viral loads, particularly around 6 log10 IU/mL, demonstrated the highest on-treatment hepatocellular carcinoma (HCC) risk. Because this conclusion is interesting and different from the findings of some previous studies,2 3 which may affect the timing of treatment initiation for many patients with CHB, findings of this study should be cautiously viewed. Here, we highlight some points that need further discussion. First, the authors investigated the association between on-treatment HCC risk and various baseline characteristics. However, some indicators (recently emerging biomarkers: quantified hepatitis B surface antigen (HBsAg)4 5; common clinical characteristics: serum albumin,2 diabetes mellitus,6 family history of HCC,

I risultati del progetto Iss “Veterani in Sella”

I risultati del progetto Iss “Veterani in Sella”

Endocrinologi, troppi timori, non si spiegano bene i vantaggi

This JAMA Clinical Guidelines Synopsis summarizes the 2023 American Association for the Study of Liver Diseases practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma.

In aumento, un terzo dei pazienti riceve diagnosi dopo 5 anni

In aumento, un terzo dei pazienti riceve diagnosi dopo 5 anni

Colpiti in 500mila, il farmaco è per forme moderate e severe

Colpiti in 500mila, il farmaco è per forme moderate e severe

Annals of Internal Medicine, Ahead of Print.